Log in to your Inderes Free account to see all free content on this page.
Modus Therapeutics Holding
0.48 SEK
-2.85 %
Less than 1K followers
MODTX
First North Stockholm
Biotechnology & Pharmaceuticals
Health Care
Overview
Financials & Estimates
Ownership
Dividend
Investor consensus
-2.85 %
+6.46 %
+56.21 %
+57.24 %
+22.56 %
-15.21 %
-52.26 %
-
-76.91 %
Modus Therapeutics operates in biotechnology. The product portfolio includes the drug candidate sevuparin. The company's focus is to develop sevuparin for patients with sepsis, septic shock and other conditions with systemic inflammation. In addition to its core business, it also offers service and related ancillary services. The business and related research are conducted with the largest presence in Sweden.
Read moreMarket cap
71.08M SEK
Turnover
240.65K SEK
Revenue
EBIT %
P/E
Dividend yield-%
Revenue and EBIT-%
Revenue
EBIT-% (adj.)
EPS and dividend
EPS (adj.)
Dividend %
Financial calendar
26.5.
2026
Interim report Q1'26
28.5.
2026
General meeting '26
26.8.
2026
Interim report Q2'26
All
Press releases
3rd party
ShowingAll content types
Modus announces outcome of exercise of warrants of series TO 2026 and receives approximately SEK 9.5 million
Notice to Annual General Meeting in Modus Therapeutics Holding
Join Inderes community
Don't miss out - create an account and get all the possible benefits
FREE account
Stock market's most popular morning newsletter
Analyst comments and recommendations
Stock comparison tool
PREMIUM account
All company reports and content
Premium tools (e.g. insider transactions & stock screener)
Model portfolio